Skip to content
No results
  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences

Preventive Medicine 2023

We use cookies to ensure that we give you the best experience on our website.
  • About Us
  • Contact Us
the-pharma-data-logo-color

Preventive Medicine 2023

  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences
the-pharma-data-logo-color
  • Research

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

  • ByThe Pharma Data
  • OnMarch 27, 2023

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent…

Read More
  • Business

Takeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

  • ByThe Pharma Data
  • OnMarch 27, 2023

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Entyvio® Pens for subcutaneous (SC) injection 108 mg / Syringes…

Read More
  • Research

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

  • ByThe Pharma Data
  • OnMarch 27, 2023

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study…

Read More
  • Regulatory

Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma

  • ByThe Pharma Data
  • OnMarch 24, 2023

Across two clinical trials 82% overall response and 35% complete response ratewere observed in Chinese patients using Calquence AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been…

Read More
  • News

Bayer expands global clinical program for darolutamide in prostate cancer

  • ByThe Pharma Data
  • OnMarch 24, 2023

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA…

Read More
  • Research

Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

  • ByThe Pharma Data
  • OnMarch 24, 2023

Dupixent®demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial  The primary and all key secondary endpoints were met in a Phase 3…

Read More
  • Business

Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan

  • ByThe Pharma Data
  • OnMarch 24, 2023

New Facility Will Strengthen Takeda’s Manufacturing and Supply Capabilities to Meet Growing Patient Need for Plasma-Derived Therapies (PDTs) in Japan and Globally  Takeda’s Largest Ever Investment in Manufacturing Capacity Expansion…

Read More
  • Press Releases

Resolutions from the Annual General Meeting of Novo Nordisk A/S

  • ByThe Pharma Data
  • OnMarch 24, 2023

At the Annual General Meeting, Helge Lund, Chair of the Board of Directors communicated:“We are very pleased with the performance of Novo Nordisk in 2022, where we continued to make…

Read More
  • Research

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

  • ByThe Pharma Data
  • OnMarch 24, 2023

Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4)…

Read More
  • Research

Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

  • ByThe Pharma Data
  • OnMarch 24, 2023

AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary…

Read More
  • News

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

  • ByThe Pharma Data
  • OnMarch 22, 2023

Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric…

Read More
Statement on Allergan Nationwide Settlement to Resolve Opioid-Related Claims
  • Business

Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer’s disease

  • ByThe Pharma Data
  • OnMarch 22, 2023

Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel The Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation…

Read More
1 2 3 4 … 106
Next
Pediatric Academic Societies Meetimg (PAS) 2023
Global Pharma & Drug Delivery Summit 2023
ACPM 2023
ECBIP 2023
The 15th Paris Hepatology Conference 2023
ASGBI annual conference 2023
37th NASPAG Annual Clinical & Research Meeting 2023
18th Congress MESOT 2023
AMGA’s 2023 Annual Conference (AC23) 

About

The Pharma Data Is An Information-Centric Website Focused Mainly On The Pharmaceutical Industry Online It Is A B2B Platform Mainly Focused On The Latest Pharmaceutical News, Press Release, Industry-Related Updates, Events, And Conferences. With The Pharma Data, You Can Get All Information That Happens In The Pharmaceutical Industry.

Advertise With Us: marketing@thepharmadata.com

Quick Links

  • News
  • Press Releases
  • Business
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Terms and Conditions

Copyright © 2023 | The Pharma Data | Marnet Technologies Pvt Ltd. | Al Rights Reserved

Facebook Twitter LinkedIn